中国癌症杂志 ›› 2021, Vol. 31 ›› Issue (11): 1104-1109.doi: 10.19401/j.cnki.1007-3639.2021.11.009

• 论著 • 上一篇    下一篇

EGFR(rs884419)基因多态性与前列腺癌临床病理学特征的相关性分析

潘 剑,韦 煜,叶定伟,朱 耀   

  1. 复旦大学附属肿瘤医院泌尿外科,复旦大学上海医学院肿瘤学系,上海 200032
  • 出版日期:2021-11-30 发布日期:2021-12-03
  • 通信作者: 朱 耀 E-mail: mailzhuyao@163.com

Correlation between EGFR (rs884419) gene polymorphism and clinicopathological characteristics of prostate cancer

PAN Jian, WEI Yu, YE Dingwei, ZHU Yao   

  1. Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Published:2021-11-30 Online:2021-12-03
  • Contact: ZHU Yao E-mail: mailzhuyao@163.com

摘要: 背景与目的:表皮生长因子受体(epidermal growth factor receptor,EGFR)基因的高表达被证明在前列腺癌中可间接促进肿瘤细胞迁移,并与较短的无转移生存期相关。但此前对于EGFR基因的研究主要集中于机制方面,很少与临床指标建立联系。对比EGFR基因在西方国家和中国前列腺癌患者中基因型的差异,同时探讨临床病理学特征与EGFR基因多态性的相关性。方法:检测EGFR(rs884419)基因在复旦大学附属肿瘤医院2014—2019年连续收治的182例前列腺癌患者外周血白细胞DNA中的多态性情况,比较中国与西方人群基因型变异的差异,并比较基因型与临床病理学特征及基线特征的相关性。结果:EGFR(rs884419)基因型为AA和AG的变异组患者相比,基因型为GG的正常组患者在初诊时为M 1期的占比更高(65.3% vs 84.2%,P < 0.05)。EGFR(rs884419)基因多态性与确诊时年龄、确诊时前列腺特异性抗原、转移负荷及Gleason评分无相关性(P > 0.05)。与美国前列腺癌患者相比,EGFR(rs884419)基因的变异频率更高(20.4% vs 79.1%,P < 0.05)。结论:EGFR基因型正常组患者初诊时M 1 期占比较变异组高,提示EGFR基因的表达差异可能参与前列腺癌转移的发生、发展过程,根据基因型理论上可以预测患者初诊时的远处转移状态;同时,与西方人群相比,中国前列腺癌患者EGFR基因的变异频率较高,对确诊后治疗效果的预测效能会更高。

关键词: 前列腺癌, 表皮生长因子受体, rs884419, 基因多态性, 临床病理学特征

Abstract: Background and purpose: In prostate cancer, the high expression of epidermal growth factor receptor (EGFR) gene is confirmed to indirectly promote the migration of tumor cells and is associated with a shorter metastasis-free survival. However, majority of previous research on the EGFR gene focused on the mechanism and rarely established links with clinical indicators. This study aimed to compare the genotype differences of EGFR gene in the western countries and Chinese prostate cancer patients, to explore the correlation between clinicopathological characteristics and EGFR gene polymorphism. Methods: The polymorphism of EGFR (RS884419) gene in peripheral blood leukocyte DNA of 182 prostate cancer patients who were treated in Fudan University Shanghai Cancer Center from 2014 to 2019 was detected to compare genotype differences of EGFR gene in prostate cancer patients between Chinese and the western populations, and to explore the correlation between clinicopathological and basic characteristics and EGFR gene polymorphism. Results: Compared with patients in the variant group with EGFR (rs884419) genotypes AA and AG, patients in the normal group with genotype GG had a higher proportion of distant metastases (M 1 stage) at diagnosis (65.3% vs 84.2%, P < 0.05); EGFR (rs884419) gene polymorphism had no correlation with age at diagnosis, prostate-specific antigen at diagnosis, metastatic load and Gleason score (P > 0.05). Compared with American prostate cancer patients, the mutation frequency of EGFR (rs884419) gene was higher (20.4% vs 79.1%, P < 0.05). Conclusion: The M 1 stage of patients at diagnosis is higher in the normal EGFR genotype group than in the variant group, suggesting that the difference in EGFR gene expression may be involved in the occurrence and development of prostate cancer metastasis. According to the genotype, the distant metastasis status of patients at the diagnosis can be predicted theoretically. And due to the high frequency of mutations in the Chinese patients, EGFR genotype has a stronger predictive value for treatment efficacy than it does in the western population.

Key words:  Prostate cancer, Epidermal growth factor receptor, rs884419, Gene polymorphism, Clinicopathological characteristics